Imaging Markers of Progression in Parkinson's Disease
暂无分享,去创建一个
D. Vaillancourt | A. Strafella | N. Bohnen | M. Politis | A. Tessitore | S. Lewis | T. Eimeren | N. Pavese | C. Ghadery
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] Kamin Kim,et al. Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease , 2019, NeuroImage.
[3] Kamin Kim,et al. The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease , 2019, NeuroImage.
[4] L. Timmermann,et al. Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson’s disease , 2019, Brain Imaging and Behavior.
[5] E. Tolosa,et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder , 2018, Neurobiology of Disease.
[6] D. Eidelberg,et al. Network imaging biomarkers: insights and clinical applications in Parkinson's disease , 2018, The Lancet Neurology.
[7] Julie M. Hall,et al. The functional network signature of heterogeneity in freezing of gait , 2018, Brain : a journal of neurology.
[8] A. Zwergal,et al. Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy , 2018, Neurology.
[9] Günther Deuschl,et al. Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study , 2018, Brain : a journal of neurology.
[10] S. Houle,et al. [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP , 2018, Brain Structure and Function.
[11] Jesper Jeppesen,et al. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study , 2018, Brain : a journal of neurology.
[12] F. Esposito,et al. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[13] Sylvain Houle,et al. Abnormal intrinsic brain functional network dynamics in Parkinson’s disease , 2017, Brain : a journal of neurology.
[14] E. Tolosa,et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study , 2017, The Lancet Neurology.
[15] F. Esposito,et al. Resting-state brain networks in patients with Parkinson's disease and impulse control disorders , 2017, Cortex.
[16] Alan A. Wilson,et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] A. Gjedde,et al. Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER , 2017, The Journal of Nuclear Medicine.
[18] D. Brooks,et al. Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients , 2017, NeuroImage: Clinical.
[19] Ofer Pasternak,et al. Progression marker of Parkinson’s disease: a 4-year multi-site imaging study , 2017, Brain : a journal of neurology.
[20] P. Fox,et al. Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis , 2017, Cortex.
[21] A. Drzezga,et al. Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging? , 2017, The Journal of Nuclear Medicine.
[22] Kamin Kim,et al. Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic losses , 2017, NeuroImage.
[23] W. Poewe,et al. Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[24] D. Brooks,et al. Decreased intestinal acetylcholinesterase in early Parkinson disease , 2017, Neurology.
[25] Luca Passamonti,et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.
[26] S. Houle,et al. Microglial activation in Parkinson’s disease using [18F]-FEPPA , 2017, Journal of Neuroinflammation.
[27] S. Houle,et al. Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes , 2017, Human brain mapping.
[28] Anthony J. Spychalla,et al. [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[29] A. Drzezga,et al. Elevated in vivo [18F]‐AV‐1451 uptake in a patient with progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[30] F. Niccolini,et al. Serotonin transporter in Parkinson's disease: A meta‐analysis of positron emission tomography studies , 2016, Annals of neurology.
[31] A. Takeda,et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET , 2016, Neurology.
[32] Clement Hamani,et al. Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson’s Disease , 2016, Front. Aging Neurosci..
[33] E. Tolosa,et al. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study , 2016, Movement disorders : official journal of the Movement Disorder Society.
[34] Nikolaus R. McFarland,et al. Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes , 2016, Neurology.
[35] A. Lees,et al. Visual dysfunction in Parkinson’s disease , 2016, Brain : a journal of neurology.
[36] I. McKeith,et al. Cholinergic and perfusion brain networks in Parkinson disease dementia , 2016, Neurology.
[37] D. Brooks,et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. , 2016, Brain : a journal of neurology.
[38] E. Tolosa,et al. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder , 2016, Annals of neurology.
[39] Nicola Pavese,et al. Age at onset and Parkinson disease phenotype , 2016, Neurology.
[40] P. Piccini,et al. Serotonin-to-dopamine transporter ratios in Parkinson disease , 2016, Neurology.
[41] J. Obeso,et al. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment , 2016, Human brain mapping.
[42] Y Ben-Shlomo,et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.
[43] Ofer Pasternak,et al. Free-water imaging in Parkinson's disease and atypical parkinsonism. , 2016, Brain : a journal of neurology.
[44] R. Albin,et al. Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[45] A. Drzezga,et al. Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits , 2015, The Journal of Nuclear Medicine.
[46] L. Timmermann,et al. A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role? , 2015, Cortex.
[47] L. Timmermann,et al. Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson’s Disease , 2015, Front. Behav. Neurosci..
[48] S. Kapur,et al. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. , 2015, Brain : a journal of neurology.
[49] J. Seibyl,et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. , 2015, Brain : a journal of neurology.
[50] Alan A. Wilson,et al. Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease , 2015, PloS one.
[51] Jae Sung Lee,et al. Putaminal serotonergic innervation , 2015, Neurology.
[52] D. Vaillancourt,et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. , 2015, Brain : a journal of neurology.
[53] Nikolaus R. McFarland,et al. Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[54] Qin Chen,et al. Functional connectome assessed using graph theory in drug-naive Parkinson’s disease , 2015, Journal of Neurology.
[55] M. Hornberger,et al. Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson’s disease: a task-based fMRI study , 2015, npj Parkinson's Disease.
[56] A. Lawrence,et al. Single versus multiple impulse control disorders in Parkinson’s disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release , 2015, Journal of Neurology.
[57] A. Björklund,et al. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study , 2015, Neurobiology of Aging.
[58] Ajay S. Kurani,et al. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy , 2015, Human brain mapping.
[59] R. Albin,et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. , 2015, JAMA neurology.
[60] D. Vaillancourt,et al. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study , 2015, Neurobiology of Aging.
[61] I. Toni,et al. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers , 2015, Neurology.
[62] E. Tolosa,et al. Cognitive impairment and resting‐state network connectivity in Parkinson's disease , 2015, Human brain mapping.
[63] D. Eidelberg,et al. Effects of levodopa on regional cerebral metabolism and blood flow , 2015, Movement disorders : official journal of the Movement Disorder Society.
[64] Marios Politis,et al. Neuroimaging in Parkinson disease: from research setting to clinical practice , 2014, Nature Reviews Neurology.
[65] A. Tessitore,et al. Resting-state fMRI sheds light on neural substrates of cognitive decline in Parkinson disease , 2014, Neurology.
[66] A. Tessitore,et al. Mini Review Article , 2022 .
[67] Stephanie Studenski,et al. Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study , 2014, Movement disorders : official journal of the Movement Disorder Society.
[68] Klaus Seppi,et al. Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI , 2014, Neurology.
[69] G. Halliday,et al. Tricks of the mind: Visual hallucinations as disorders of attention , 2014, Progress in Neurobiology.
[70] G. Halliday,et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease , 2014, Human brain mapping.
[71] R. Mehanna. Gait speed in Parkinson disease correlates with cholinergic degeneration , 2014, Neurology.
[72] Antonio P Strafella,et al. Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. , 2014, Brain : a journal of neurology.
[73] F. Turkheimer,et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.
[74] S. Houle,et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. , 2014, Brain : a journal of neurology.
[75] G. Stebbins,et al. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging , 2014, Movement disorders : official journal of the Movement Disorder Society.
[76] S. Studenski,et al. Gait speed in Parkinson disease correlates with cholinergic degeneration , 2013, Neurology.
[77] Joel S Perlmutter,et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases , 2013, Neurology.
[78] R. Bowtell,et al. Visualization of nigrosome 1 and its loss in PD , 2013, Neurology.
[79] C. Adler,et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.
[80] T. Robbins,et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[81] Fabrizio Esposito,et al. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. , 2013, Brain : a journal of neurology.
[82] Martin Sarter,et al. Leveraging the cortical cholinergic system to enhance attention , 2013, Neuropharmacology.
[83] D. Perani,et al. Faculty Opinions recommendation of [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. , 2012 .
[84] Fabrizio Esposito,et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease , 2012, Neurology.
[85] N. Cairns,et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. , 2012, Archives of neurology.
[86] R. Buchert,et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism , 2012, Neurology.
[87] R. Albin,et al. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia , 2012, Neurology.
[88] S. Gilman,et al. Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[89] G. Frisoni,et al. Resting state fMRI in Alzheimer's disease: beyond the default mode network , 2012, Neurobiology of Aging.
[90] Ehren L. Newman,et al. Cholinergic modulation of cognitive processing: insights drawn from computational models , 2012, Front. Behav. Neurosci..
[91] Alan A. Wilson,et al. Translocator Protein (18 kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [18F]-FEPPA , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[92] Fabrizio Esposito,et al. Interaction between aging and neurodegeneration in amyotrophic lateral sclerosis , 2012, Neurobiology of Aging.
[93] G. H. Halliday,et al. Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm , 2012, Movement disorders : official journal of the Movement Disorder Society.
[94] Igor D. Grachev,et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo , 2012, Neurobiology of Aging.
[95] M. Mikl,et al. The default mode network integrity in patients with Parkinson’s disease is levodopa equivalent dose-dependent , 2012, Journal of Neural Transmission.
[96] D. Burn,et al. The interplay of cholinergic function, attention, and falls in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[97] V. Menon. Large-scale brain networks and psychopathology: a unifying triple network model , 2011, Trends in Cognitive Sciences.
[98] O. Lindvall,et al. Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.
[99] Marios Politis,et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.
[100] M. Politis. C O M M E N T a R Y Open Access , 2022 .
[101] Angie A. Kehagia,et al. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease , 2010, The Lancet Neurology.
[102] D. Vaillancourt,et al. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease , 2010, Human brain mapping.
[103] N. Cairns,et al. Amyloid imaging of Lewy body‐associated disorders , 2010, Movement disorders : official journal of the Movement Disorder Society.
[104] S. Houle,et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD , 2010, Neurology.
[105] F. Horak,et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease , 2010, Neurology.
[106] S. Lehéricy,et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. , 2010, The Journal of clinical investigation.
[107] Marios Politis,et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.
[108] M. Filippi,et al. Default-mode network dysfunction and cognitive impairment in progressive MS , 2010, Neurology.
[109] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.
[110] S. Studenski,et al. History of falls in Parkinson disease is associated with reduced cholinergic activity , 2009, Neurology.
[111] R. Pearce,et al. The morbid anatomy of dementia in Parkinson’s disease , 2009, Acta Neuropathologica.
[112] T. Suhara,et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET , 2009, Neuroscience Research.
[113] Oury Monchi,et al. Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. , 2009, Archives of neurology.
[114] S. Houle,et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.
[115] David J. Brooks,et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study , 2008, Experimental Neurology.
[116] G. Bernardi,et al. Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms , 2008, The European journal of neuroscience.
[117] V. Menon,et al. A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks , 2008, Proceedings of the National Academy of Sciences.
[118] G. Glover,et al. Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus , 2007, Biological Psychiatry.
[119] Kristina M. Visscher,et al. A Core System for the Implementation of Task Sets , 2006, Neuron.
[120] Jeffrey M. Hausdorff,et al. Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects of gait are attention demanding? , 2005, The European journal of neuroscience.
[121] Maurizio Corbetta,et al. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[122] J. Berger-Sweeney. The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers , 2003, Neuroscience & Biobehavioral Reviews.
[123] Alan A. Wilson,et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.
[124] D J Wyper,et al. Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.
[125] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[126] Eileen O. Smith,et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.
[127] N. Weiner,et al. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. , 1993, The Journal of pharmacology and experimental therapeutics.
[128] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[129] Young T. Hong,et al. 18 FAV-1451 positron emission tomography in Alzheimer ’ s disease and progressive supranuclear palsy , 2017 .
[130] T. Foltynie,et al. The ongoing pursuit of neuroprotective therapies in Parkinson disease , 2015, Nature Reviews Neurology.
[131] F. Esposito,et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease , 2014, Journal of Neurology.
[132] David Eidelberg,et al. Abnormal metabolic brain networks in Parkinson's disease from blackboard to bedside. , 2010, Progress in brain research.
[133] I. Podreka,et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .
[134] S. Asenbaum,et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.